Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Eli Lilly presents olanzapine LAI data

Eli Lilly presents olanzapine LAI data

23rd June 2008

Eli Lilly has announced the results from clinical trials of olanzapine long-acting injection (LAI) at the first annual conference of the Schizophrenia International Research Society.

Zyprexa (olanzapine) was introduced in 1995 and since its launch has been prescribed to around 24 million people worldwide, while olanzapine LAI is an investigational formulation of the compound that combines it with a pamoate salt to result in extended delivery of the drug.

Regulatory reviews of this new formulation are currently ongoing in the EU, US, Canada and Australia.

Trial results from a 24-week maintenance study showed the safety and efficacy profile of olanzapine LAI to be generally consistent of that of Zyprexa, with the exception injection-related events.

David McDonnell, clinical research physician at Eli Lilly, said: “These studies offer insight into the potential of olanzapine LAI as a maintenance treatment for patients with schizophrenia who may have difficulty taking medication on a daily basis.”

He added that schizophrenia is a complex and challenging disease to manage, with it important to discover new methods enhance patient compliance with their medication.

In March 2008, Eli Lilly announced a successful resolution of its ongoing mediation relating to the use of Zyprexa following the filing of a lawsuit by the State of Alaska regarding the use of the compound by its Medicaid programme.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.